Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Prostate Cancer
•
Medical Oncology
Do you approach high-grade foamy gland prostatic adenocarcinoma with desmoplastic stroma, either localized or metastatic, differently than standard prostatic adenocarcinoma?
Related Questions
Under what circumstances would you treat prostate cancer without a biopsy?
Are there any contraindications to Pluvicto therapy you personally use, given that there are none directly provided by the manufacturer?
How do you manage PSA progression while a patient is on xofigo or pluvicto?
What duration androgen deprivation do you recommend with salvage pelvic radiotherapy for pelvic node relapse after prostatectomy?
For an older patient with hormone-sensitive high-volume, high-risk prostate cancer with metastases to bone who developed toxicity with enzalutamide, what other oral AR blocker would you offer?
What are your top takeaways from ASCO GU 2025?
Do you add ADT to RT for a patient with intermediate-risk prostate cancer with discordant Decipher and ArteraAI results?
Given results of the RADICALS trials, is LT-ADT standard of care for salvage prostate RT?
How do you interpret recent large retrospective analyses comparing radical prostatectomy vs. radiation for prostate cancer?
What are your top takeaways in GU Cancers from ESMO 2024?
